N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction?

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Clinical Chemistry

• Publication date

  2005-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1373/CLINCHEM.2005.050153PMID 15932966
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Quantitative radionuclide angiocardiography

  2007cited by this paper
• Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review.

  2004cited by this paper
• Cardiotoxicity of cytotoxic drugs.

  2004cited by this paper
• Troponin-T and brain natriuretic peptide as predictors for adriamycin-induced cardiomyopathy in rats.

  2004cited by this paper
• Subclinical late cardiomyopathy after doxorubicin therapy for lymphoma in adults.

  2004cited by this paper
• Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy

  2004cited by this paper
• Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy.

  2003cited by this paper
• Natriuretic peptides during the development of doxorubicin‐induced left ventricular diastolic dysfunction

  2002cited by this paper
• Pathophysiological and Clinical Relevance of Circulating Levels of Cardiac Natriuretic Hormones: Are They Merely Markers of Cardiac Disease?

  2002cited by this paper
• Guidelines for the diagnosis and treatment of chronic heart failure.

  2001cited by this paper
• Prospective evaluation of early cardiac damage induced by epirubicin-containing adjuvant chemotherapy and locoregional radiotherapy in breast cancer patients.

  2001cited by this paper
• Brain Natriuretic Peptide Is a Predictor of Anthracycline-Induced Cardiotoxicity

  2001cited by this paper
• Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer.

  2001cited by this paper
• The Impact of Cardiac Natriuretic Peptide Determination on the Diagnosis and Management of Heart Failure

  2001cited by this paper
• Cardiotoxicity of Chemotherapeutic Agents

  2000cited by this paper
• Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.

  2000cited by this paper
• Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy.

  2000cited by this paper
• Cardiac Toxicity after Anthracycline Chemotherapy in Childhood

  2000cited by this paper
• Assessment of cardiotoxicity during haemopoietic stem cell transplantation with plasma brain natriuretic peptide

  2000cited by this paper
• Natriuretic peptides as markers of cardiotoxicity during doxorubicin treatment for non‐Hodgkin's lymphoma

  1999cited by this paper
• Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction. Comparison with plasma angiotensin II and endothelin-1.

  1999cited by this paper
• Strategies for reduction of anthracycline cardiac toxicity.

  1998cited by this paper
• Measurement and significance of circulating natriuretic peptides in cardiovascular disease.

  1998cited by this paper
• Acute neurohumoral and cardiovascular effects of idarubicin in leukemia patients

  1998cited by this paper
• Doxorubicin-induced cardiomyopathy.

  1998cited by this paper
• Elevated B-type natriuretic peptide levels after anthracycline administration.

  1998cited by this paper
• Review of tests for monitoring doxorubicin-induced cardiomyopathy.

  1996cited by this paper
• Anthracyclines and the heart.

  1993cited by this paper
• Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction.

  1993cited by this paper
• Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.

  1992cited by this paper
• Atrial natriuretic peptide as a marker for doxorubicin‐induced cardiotoxic effects

  1992cited by this paper
• Cardiac toxicity 4 to 20 years after completing anthracycline therapy.

  1991cited by this paper
• Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy. Seven-year experience using serial radionuclide angiocardiography.

  1987cited by this paper
• Doxorubicin cardiac toxicity manifesting seven years after treatment. Case report and review.

  1986cited by this paper
• Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

  1986cited by this paper
• Sensitivity and specificity of radionuclide ejection fractions in doxorubicin cardiotoxicity.

  1983cited by this paper
• Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.

  1979cited by this paper

• Biomarkers for cancer therapy-related cardiovascular toxicity.

  2026cites this paper
• A New Era of Biomarkers in Cardio-Oncology

  2026cites this paper
• Effect of cyclophospamide, doxorubicin, vincristine and prednisone/prednisolone (CHOP) chemotherapy regimens on left ventricular systolic function and cardiac structural abnormalities in non-Hodgkin lymphoma patients

  2025cites this paper
• Exploring Predictive Risk Factors for Myocardial Injury in Children Treated with Anthracyclines: A Pilot Study

  2025influential citation
• Advances in Cardioprotection Strategies: Focusing on Breast Cancer and Beyond Through Novel Biomarkers and Pharmacological Approaches

  2025cites this paper
• Anthracycline-induced cardiomyopathy: risk prediction, prevention and treatment

  2025influential citation
• Comparative Analysis of Speckle-tracking Echocardiography and Cardio-specific Markers for Early Detection of Cardiotoxicity in Patients With Breast Cancer

  2025cites this paper
• Novel PLGA-based nanoformulation decreases doxorubicin-induced cardiotoxicity.

  2024cites this paper
• Chemotherapy Related Cardiotoxicity Evaluation—A Contemporary Review with a Focus on Cardiac Imaging

  2024cites this paper
• Cardiac and noncardiac biomarkers in patients undergoing anthracycline chemotherapy – a prospective analysis

  2023cites this paper
• Serum Copeptin in Cardiooncology Practice: Review of Pathophysiological and Clinical Implications

  2023cites this paper
• Cardiotoxicity: Importance of biomarkers

  2023cites this paper
• Revisiting treatment-related cardiotoxicity in patients with malignant lymphoma—a review and prospects for the future

  2023cites this paper
• Recent advances in the Prevention and Treatment of Chemotherapy–induced Cardiotoxicity

  2023cites this paper
• NATRIURETIC PEPTIDES: ANOTHER TOOL FOR THE MANAGEMENT OF CANCER?

  2023cites this paper
• Risk and Management of Patients with Cancer and Heart Disease

  2023cites this paper
• Electrocardiographic and biochemical analysis of anthracycline induced cardiotoxicity in breast cancer patients from Southern Sri Lanka

  2023cites this paper
• Role of Cardiac Biomarkers in Monitoring Cardiotoxicity in Chemotherapy Patients

  2023cites this paper
• Multimodality Imaging for Cardiotoxicity: State of the Art and Future Perspectives

  2022cites this paper
• Current Status and Trends of Research on Anthracycline-Induced Cardiotoxicity from 2002 to 2021: A Twenty-Year Bibliometric and Visualization Analysis

  2022cites this paper
• Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population

  2022cites this paper
• Investigation of cardiac dysfunction in women with metastatic breast cancer under treatment with monoclonal antibodies.

  2022cites this paper
• The effects of low‐dose anthracycline‐based chemotherapy on the levels of serum NT‐proBNP level and left ventricular systolic and diastolic dysfunctions: A prospective observational study

  2022cites this paper
• Diagnostic Value of sST2, VCAM-1, and Adiponectin in Patients with Breast Cancer to Predict Anti-Tumour Treatment-Related Cardiac Events: A Pilot Study

  2022cites this paper
• Place des marqueurs biologiques en cardiologie

  2022cites this paper
• GDF-15, hs-TnT and NT proBNP for Predicting Risk of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy.

  2022cites this paper
• Radiation-induced lipoprotein-associated phospholipase A2 increases lysophosphatidylcholine and induces endothelial cell damage.

  2021cites this paper
• Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies

  2021cites this paper
• Subclinical left ventricular dysfunction in men under androgen deprivation therapy for prostate cancer, revealed by speckle‐tracking‐derived parameters, repolarization, and myocardial injury markers

  2021cites this paper
• Adjuvant breast cancer treatments cardiotoxicity and modern methods of detection and prevention of cardiac complications

  2021cites this paper
• BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and/or Trastuzumab

  2021cites this paper
• N-Terminal Pro-Brain Natriuretic Peptide Plasma Levels Are Associated with Intermediate-Term Follow-Up Cancer in Coronary Patients

  2021cites this paper
• Cardiovascular toxicity induced by chemotherapy and target drugs: mechanisms, diagnostic and preventive approaches

  2021cites this paper
• Study and cardiovascular follow-up of children and adolescents undergoing oncohematological treatments: Why, how, and when?

  2021cites this paper
• The role of cardiac biomarkers in early detection of cardiotoxicity in breast cancer treated with trastuzumab in the adjuvant setting: a systematic review

  2021cites this paper
• Cardiovascular Health

  2021cites this paper
• Circulating Biomarkers for Cardiotoxicity Risk Prediction

  2021cites this paper
• Cardiotoxicity: A Major Setback in Childhood Leukemia Treatment

  2021cites this paper
• Assessment and Management of Cardiotoxicity in Hematologic Malignancies

  2021cites this paper
• Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity

  2021cites this paper
• R‐COMP versus R‐CHOP as first‐line therapy for diffuse large B‐cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group

  2021cites this paper
• British Society for Echocardiography and British Cardio-Oncology Society guideline for transthoracic echocardiographic assessment of adult cancer patients receiving anthracyclines and/or trastuzumab

  2021cites this paper
• Preventive Cardio-Oncology: Cardiovascular Disease Prevention in Cancer Patients and Survivors

  2021cites this paper
• Personalized Approach to Cancer Treatment–Related Cardiomyopathy

  2020cites this paper
• Practical guidance for echocardiography for cancer therapeutics-related cardiac dysfunction

  2020cites this paper
• Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the GeparOcto‐GBG 84 Trial

  2020cites this paper
• Cardio-Oncology

  2020cites this paper
• [Сurrent views on predictors and biomarkers of early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer (review of literature).]

  2020cites this paper
• Troponins and natriuretic peptides to detect cardiotoxicity: useful biomarkers or paradise lost?

  2020cites this paper
• Cardiovascular risk assessment and management of patients undergoing hematopoietic cell transplantation

  2020cites this paper
• Troponins and Natriuretic Peptides in Cardio-Oncology Patients—Data From the ECoR Registry

  2020cites this paper
• Cardiovascular toxicity induced by anti-VEGF/VEGFR agents: a special focus on definitions, diagnoses, mechanisms and management

  2020cites this paper
• The Role of Biomarkers in Cardio-Oncology

  2020cites this paper
• Anthracycline-induced cardiotoxicity: mechanisms of action, incidence, risk factors, prevention, and treatment

  2020cites this paper
• Speckle-tracking derived parameters of left ventricular function, repolarization and myocardial injury markers during androgen deprivation therapy

  2020cites this paper
• Strategies to Prevent Cardiovascular Toxicity in Breast Cancer: Is It Ready for Primetime?

  2020cites this paper
• Optimizing Cardiovascular Health in Patients With Cancer: A Practical Review of Risk Assessment, Monitoring, and Prevention of Cancer Treatment-Related Cardiovascular Toxicity.

  2020cites this paper
• Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and the Cardio‐Oncology Council of the European Society of Cardiology

  2020cites this paper
• Cytotoxic-Induced Heart Failure among Breast Cancer Patients in Nigeria: A Call to Prevent Today’s Cancer Patients from Being Tomorrow’s Cardiac Patients

  2020cites this paper
• Non-Invasive Hemodynamic Whole-Body Bioimpedance Indices for the Early Detection of Cancer Treatment-Related Cardiotoxicity: A Retrospective Observational Study

  2020cites this paper
• Cardiotoxicity of Anthracyclines

  2020cites this paper
• Early Detection of Myocardial Damage: A Multimodality Approach

  2020cites this paper
• Complications cardiaques des traitements anticancéreux

  2020cites this paper
• Role of biomarkers and electrocardiography assessment as individual predictors of anthracycline cardiotoxicity in lymphoma patients

  2019cites this paper
• Oncologic therapies associated with cardiac toxicities: how to minimize the risks

  2019cites this paper
• Doxorubicin-Induced Cardiomyopathy in Children.

  2019cites this paper
• Precision Cardio-Oncology

  2019cites this paper
• Chronic cardiovascular toxicity in the older oncology patient population.

  2019cites this paper
• Myocardial dysfunction in long‐term breast cancer survivors treated at ages 40–50 years

  2019cites this paper
• Role of Cardiovascular Biomarkers in the Risk Stratification, Monitoring, and Management of Patients with Cancer.

  2019cites this paper
• The cardiotoxicity effect of different chemotherapeutic regimens in Iraqi patients with breast cancer: A follow up study

  2019cites this paper
• The correlation of doxorubicin related cardiotoxicity with B-type natriuretic peptide levels in South Indian population

  2019cites this paper
• State of the Art: Precision Cardio-Oncology

  2019cites this paper
• Recent advances in cardio‐oncology: a report from the ‘Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019’

  2019cites this paper
• Cardiac Toxicity of HER-2 Targeted Regimens

  2019cites this paper
• Cardioprotective Approaches to the Management of Patients with Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Do We Need Increased Surveillance in Elderly Women on Trastuzumab?

  2018cites this paper
• Early Detection of Cardiac Damage

  2018cites this paper
• Biomarker Discovery in Cardio-Oncology

  2018cites this paper
• Cardiac toxicity of HER2-targeted regimens

  2018cites this paper
• Diagnosis, Treatment, and Prevention of Cardiovascular Toxicity Related to Anti-Cancer Treatment in Clinical Practice: An Opinion Paper from the Working Group on Cardio-Oncology of the Korean Society of Echocardiography

  2018cites this paper
• Update on Incorporating Biomarkers with Imaging Findings for the Detection and Management of Cardiotoxicity

  2018cites this paper
• The role of cardiac biomarkers in cardio-oncology.

  2018cites this paper
• Cardio Protective Effect of Neuregillin-1 against Cardio Toxicity Induced by Trastuzumab in Adult Mice

  2018cites this paper
• Biomarkers in cancer therapy related cardiac dysfunction (CTRCD)

  2018cites this paper
• Evaluation of the impact of treatment with hematopoietic stem cells transplantation (HSCT) on biochemical markers of heart function and novel electrocardiographic markers of repolarization in patients with hematological malignancies

  2018cites this paper
• Subclinical Left Ventricular Dysfunction During Chemotherapy

  2018cites this paper
• Role of Biomarkers in Prediction of Cardiotoxicity During Cancer Treatment

  2018cites this paper
• The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT

  2018cites this paper
• Management of Advanced Heart Failure in a Cancer Patient

  2017cites this paper
• Diagnostic Strategies for Early Recognition of Cancer Therapeutics–Related Cardiac Dysfunction

  2017cites this paper
• Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline.

  2017cites this paper
• Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts

  2017cites this paper
• Biomarkers for monitoring chemotherapy-induced cardiotoxicity

  2017cites this paper
• Using biomarkers and early prophylactic treatment to prevent cardiotoxicity in cancer patients on chemotherapy : biomarkers : detection and treatment of cardiotoxicity

  2017cites this paper
• From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview

  2017cites this paper
• Title The Role of Biomarkers in Detection of Cardiotoxicity

  2017cites this paper
• Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study

  2017cites this paper
• Cardiac Imaging: Multimodality Advances and Surveillance Strategies in Detection of Cardiotoxicity

  2017cites this paper
• Reduction of Doxorubicin-Induced Cardiotoxicity Using Nanocarriers: A Review.

  2017cites this paper
• Updates in heart failure: Highlights from the Iranian Joint Cardiovascular Congress Tehran, Iran, 1-4 March 2016.

  2017cites this paper